” S e s e n B i o R e p o r t s G A A P E P S o f – $ 0 . 0 4 , B e a t i n g E x p e c t a t i o n s b y $ 0
March 5, 2023
Trending News 🌥️
Sesen Bio ($NASDAQ:SESN), a life sciences company focused on developing cancer therapies, recently released its fourth quarter financial report and beat expectations with a GAAP Earnings Per Share of -$0.04. Sesen Bio’s portfolio of cancer treatments under development and its progress in clinical trials are believed to have had a positive impact on its performance as the company prepared for its next phase of commercialization. The company also announced several strategic collaborations during the quarter, including a multi-year collaboration deal with Boehringer Ingelheim and the establishment of a Joint Venture called JVentives with Harvest Moon Ventures.
These collaborations are expected to help the company enhance its research and development capabilities and gain access to new markets. Investors are optimistic that the company will be able to further accelerate its development plans and capture a larger share of the cancer treatment industry.
Share Price
Though the company’s stock opened at $0.6 and closed at $0.6, it was still down 0.6% from the last closing price of 0.6. Despite the small decline, SESEN BIO still managed to beat analyst expectations. Despite the strong results, investors remain cautious as the company continues to face a challenging market environment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sesen Bio. More…
| Total Revenues | Net Income | Net Margin |
| 40 | -19.88 | -75.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sesen Bio. More…
| Operations | Investing | Financing |
| 24.89 | -53.97 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sesen Bio. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 189.17 | 30.98 | 0.78 |
Key Ratios Snapshot
Some of the financial key ratios for Sesen Bio are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 197.9% | – | -96.0% |
| FCF Margin | ROE | ROA |
| 62.2% | -14.8% | -12.7% |
Analysis
At GoodWhale, we conducted an in-depth analysis of SESEN BIO‘s wellbeing. Our results show that SESEN BIO is a high risk investment in terms of its financial and business aspects. Our Risk Rating tool highlighted four major risk warnings in the income sheet, balance sheet, cashflow statement and financial journal. If you would like to learn more about our findings, be sure to register with us to access our detailed report. Our customers can also take advantage of our financial advice and portfolio management service. We strive to help you make the best decisions when it comes to investing in SESEN BIO. More…
Peers
The healthcare sector is competitive, and companies are always vying for market share. Sesen Bio Inc is no different, and it competes against Gossamer Bio Inc, Galmed Pharmaceuticals Ltd, and ARCA biopharma Inc. in the development and commercialization of treatments for cancer and other diseases. While each company has its own strengths and weaknesses, Sesen Bio Inc has proven to be a formidable competitor.
– Gossamer Bio Inc ($NASDAQ:GOSS)
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of immunology, inflammation and oncology. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.
As of 2022, Gossamer Bio has a market cap of 1.17B and a ROE of -3124.66%. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.
– Galmed Pharmaceuticals Ltd ($NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic solutions targeting liver diseases. The company’s lead product candidate, Aramchol, is a once-daily, oral treatment for non-alcoholic steatohepatitis (NASH). Galmed is planning to initiate a Phase III clinical trial for Aramchol in 2020. The company has a market cap of 9.04M as of 2022 and a Return on Equity of -111.62%.
– ARCA biopharma Inc ($NASDAQ:ABIO)
ACRA biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of cancer and other diseases. The company has a market cap of 29.54M as of 2022 and a Return on Equity of -22.71%. ACRA biopharma Inc was founded in 2006 and is headquartered in San Diego, CA.
Summary
This impressive performance was achieved due to an increase in revenue driven by the company’s recent investments in research and development and new product launches. Going forward, Sesen Bio‘s strategy of leveraging its existing assets to create value for shareholders is expected to drive growth in earnings, as well as further advancement in the development of therapeutic solutions for patients. The company is confident that future investments in research and development will enable them to remain on track for success. Investors should keep a close eye on Sesen Bio for a potential upside in their portfolio.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
